Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005023 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
A Phase 1 study of Breast Cancer and Lung Cancer, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00005023: Completed Phase 1 study of Breast Cancer and Lung Cancer, sponsored by University of Washington.
NCT00005023 is a Phase 1 study of Breast Cancer and Lung Cancer that has completed, run by University of Washington. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005023, a Phase 1 study of Breast Cancer and Lung Cancer, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Vaccines may make the body build an immune response to tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus sargramostim in treating patients who have stage III or stage IV cancer.
Conditions Studied
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL HER-2/neu peptide vaccine
Study Locations (1)
Washington
- University of Washington School of Medicine - Seattle
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-03 |
| Est. Completion | 2001-01 |
| Phase | Phase 1 |
What the finished NCT00005023 record still lists
NCT00005023 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which sargramostim is the first listed.
NCT00005023 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00005023 about?
NCT00005023 is a clinical study titled "Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer". RATIONALE: Vaccines may make the body build an immune response to tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus sargramostim in trea...
What is the current status of trial NCT00005023?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-03. Estimated completion is 2001-01.
What conditions does trial NCT00005023 study?
This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Ovarian Cancer.
What interventions are being tested in trial NCT00005023?
The interventions under investigation include: sargramostim (BIOLOGICAL), HER-2/neu peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005023?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005023 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia